Looks at how gut microbiota and microbial metabolites relate to multiple sclerosis phenotypes and outlines translational research priorities.
Key Takeaways
- Bacterially derived metabolites such as short-chain fatty acids
- Recent longitudinal studies also show associations between metabolite profiles and disability worsening
- Interventional studies that are needed to enable microbiome-informed precision therapies in MS